Trials / Terminated
TerminatedNCT02485990
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma).
Detailed description
This clinical trial was initially intended to be a Phase 1/2 trial, but the trial never moved forward to Phase 2 prior to termination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tremelimumab | |
| DRUG | Olaparib |
Timeline
- Start date
- 2016-01-08
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
- First posted
- 2015-06-30
- Last updated
- 2021-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02485990. Inclusion in this directory is not an endorsement.